Division of Respirology, Department of Medicine, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario, M5B 1W8, Canada.
Keenan Research Centre in the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada.
J Gen Intern Med. 2024 Nov;39(14):2716-2723. doi: 10.1007/s11606-024-08978-2. Epub 2024 Aug 14.
Some have advocated that nabilone be used rather than opioids to manage chronic, noncancer pain, since the former drug may have a better safety profile.
We compared the safety of incident nabilone use relative to incident opioid use with respect to multiple clinically important outcomes.
A population-based, retrospective cohort study.
Province of Ontario, Canada.
Persons aged 12 years and older, diagnosed with a musculoskeletal condition within the past 3 years prior to the index date.
Incident nabilone use, with incident opioid use serving as the reference group.
Within 3 months following the index date, we separately evaluated for pneumonia, motor vehicle accidents, falls or fractures, mental and behavioral disorder due to psychoactive substance use, and all-cause mortality.
A total of 18,863 incident nabilone users were propensity score matched to an equal number of opioid users. In the overall matched analysis, incident nabilone users vs. incident opioid users had significantly lower rates of pneumonia (hazard ratio [HR] 0.78, 95% CI 0.63-0.96), falls or fractures (HR 0.56, 95% CI 0.50-0.64), and all-cause mortality (HR 0.79, 95% CI 0.65-0.95), but significantly higher rate of mental or behavioral disorder (HR 2.23, 95% CI 1.45-3.43). There was no significant difference between groups with respect to rate of motor vehicle accidents.
Unmeasured confounding may have influenced results.
While usage of nabilone relative to opioids was associated with reduced rates of pneumonia, falls or fractures, and all-cause mortality, it was simultaneously associated with an increased rate of adverse mental health outcomes. This picture of mixed safety results raises concerns with the policy approach of broadly substituting use of opioids with nabilone.
Ontario Ministry of Health.
有人主张,与阿片类药物相比,纳布啡用于治疗慢性非癌性疼痛可能更安全,因为前者可能具有更好的安全性。
我们比较了新诊断使用纳布啡和新诊断使用阿片类药物的安全性,主要针对多种临床重要结局。
基于人群的回顾性队列研究。
加拿大安大略省。
年龄在 12 岁及以上,在索引日期前的过去 3 年内被诊断为肌肉骨骼疾病。
新诊断使用纳布啡,以新诊断使用阿片类药物作为参照组。
在索引日期后的 3 个月内,我们分别评估肺炎、机动车事故、跌倒或骨折、精神和行为障碍与精神活性物质使用以及全因死亡率。
共 18863 例新诊断纳布啡使用者与 18863 例新诊断阿片类药物使用者进行倾向评分匹配。在整体匹配分析中,与新诊断使用阿片类药物相比,新诊断使用纳布啡的患者肺炎发生率显著降低(风险比 [HR]0.78,95%置信区间 [CI]0.63-0.96)、跌倒或骨折发生率显著降低(HR0.56,95%CI0.50-0.64)和全因死亡率显著降低(HR0.79,95%CI0.65-0.95),但精神或行为障碍发生率显著升高(HR2.23,95%CI1.45-3.43)。两组在机动车事故发生率方面没有显著差异。
未测量的混杂因素可能影响结果。
与使用阿片类药物相比,纳布啡的使用与肺炎、跌倒或骨折和全因死亡率的降低相关,但同时与不良心理健康结局的发生率增加相关。这种混杂的安全性结果引起了对广泛用纳布啡替代阿片类药物政策方法的关注。
安大略省卫生部。